Abstract 6160: Design and preclinical evaluation of a first-in-class covalent reversible inhibitor of IRAK4 with immunomodulatory properties and selective anti-lymphoma effect
Gema Gorjón-de-Pablo, Núria Profitós-Pelejà, M. H. Jacobs, Aitor Gonzalez-Herrero, Jeronimo Parra, Elisabetta Mereu, P. Escobar Cifuentes, Melissa Orphali, Jordi Teixidó, Manel Esteller, José I. Borrell, Roger Estrada‐Tejedor, Gaël Roué (2025). Abstract 6160: Design and preclinical evaluation of a first-in-class covalent reversible inhibitor of IRAK4 with immunomodulatory properties and selective anti-lymphoma effect. , 85(8_Supplement_1), DOI: https://doi.org/10.1158/1538-7445.am2025-6160.
